Daniel Posker

Special Counsel
Norton Rose Fulbright Australia

Sydney
Australia
T:+61 2 9330 8866
Sydney
Australia
T:+61 2 9330 8866
Daniel Posker

Daniel Posker

LinkedIn vCard

Related services and key industries

Related services



Key industry sectors



Biography

Daniel Posker is an intellectual property disputes lawyer based in Sydney with 18 years of intellectual property experience at leading global and boutique law firms in Australia and in the UK. 

Dan is experienced in all major forms of intellectual property and related rights. He acts for clients in multi-jurisdiction, high stakes and technically complex patent litigations such as the Australian iterations of Merck Sharp & Dohme v Pfizer concerning pneumococcal conjugate vaccines and Gilead v Idenix concerning Gilead's "game changer" Hepatitis C antivirals, and for HTC/S3 Graphics during the "smart phone wars" in the UK and Europe. Dan also acts in trade mark, copyright, Australian Consumer Law and trade secret disputes and often advises in relation to misleading or deceptive advertising, product launch disruption, ambush and comparative advertising, unconscionable conduct and the development and enforcement of brand protection strategies.

Dan has a busy pro bono practice and has advised a wide variety of clients including several prominent authors, Indigenous leaders and artists, the Art Gallery of New South Wales, a former Archibald prize winner, and the Arts Law Centre (for which he received a pro bono award in 2010). In addition, Dan regularly contributes to research and working groups on a number of topics including investigating potential legal protection for indigenous traditional knowledge in Australia. In 2015, Dan completed a Jawun secondment in Kununurra, Western Australia, working with various stakeholders including local and national indigenous organisations and the Western Australian and Commonwealth governments. Dan is a current member of AIPPI's Standing Committee on IP and Genetic Resources, Traditional Knowledge & Traditional Cultural Expressions.

Dan is recognised in Best Lawyers for Intellectual Property Law in Australia (2022, 2023, 2024).

Professional experience

Expand all Collapse all
  • Bachelor of Laws (first class honours), University of Technology Sydney (2006)
  • Bachelor of Science (Biotechnology), University of Technology Sydney (2006)
  • Supreme Court of New South Wales 2006
  • High Court of Australia 2008
  • Angel v SenSen (ongoing) – Patent enforcement action concerning casino game table management systems using AI / machine learning technologies.
  • Pfizer v Samsung Bioepis (ongoing) – Patent enforcement action concerning a biosimilar of ENBREL (etanercept).
  • Wyeth v Merck, Sharp & Dohme (2021) – Full Court appeal proceedings concerning pneumococcal conjugate vaccines. 
  • Merck, Sharp & Dohme v Pfizer (2021) – Patent enforcement and validity proceedings concerning the threatened launch of a pneumococcal conjugate vaccine.
  • Samsung Bioepis v Fresenius Kabi (2019) – Biosimilar on biosimilar patent revocation concerning formulations for adalimumab. 
  • Sanofi-Aventis v Alphapharm (Mylan) [2018] FCA 1426 – Obtained a broadly significant decision limiting the scope of documents that generic challengers can obtain by way of a notice to produce in the context of a preliminary injunction application.
  • AUSTRAC v Tabcorp Limited – Australia's first AML/CTF prosecution under the Anti-Money Laundering and Counter-Terrorism Financing Act 2006 (Cth) brought by the Australian Transaction Reports & Analysis Centre (AUSTRAC) in the Federal Court of Australia.
  • Gilead v Idenix (2016) 117 IPR 252; Idenix v Gilead (2017) 134 IPR 1 – Patent revocation and infringement proceedings to "clear the path" for Gilead's SOVALDI (sofosbuvir) & HARVONI (ledipasvir/sofosbuvir) treatments for HCV infection. 
  • HAVAIANAS brand protection strategy – Acted for the Brazilian owners of the HAVAIANAS brand over a number of years against importers and sellers of grey and counterfeit goods in Australia including commencing copyright infringement proceedings in the Federal Court of Australia in relation to goods seized at the border by the Australian Border Force.
  • S3 Graphics v Apple Inc (2012) – Coordinated the European phase of HTC's S3 Graphics (offensive) patent actions, including commencing multiple actions in German patent courts and obtaining a discovery order in the US District Court (ND Cal) under USC 1782 (US discovery in aid of foreign proceedings).
  • GlaxoSmithKline v Coca-Cola Enterprises (2011) – Urgent interim injunction application in the English High Court of Justice concerning trade mark and copyright infringement and passing off (LUCOZADE ENERGY vs. POWERADE ENERGY).
  • Boehringer Ingelheim v Freeman – Supreme Court of Queensland confidential information/trade secret proceedings concerning equitable rights in proprietary Duboisia plants used in the production of BUSCOPAN (hyoscine butylbromide). 
  • Best Lawyers, Intellectual Property Law, Australia (2022 - 2024)
  • Biosimilars – Market Entry and Litigation Strategies, Pharmaceutical Law, Reform & Regulation conference, 2016
  • Genes, patents and ethics, University of Technology, Sydney, Guest Lecturer, 2009
     
  • Intellectual Property Society of Australia & New Zealand (IPSANZ)
  • Association Internationale pour la Protection de la Propriété Intellectuelle (AIPPI)
  • Member, AIPPI Standing Committee on IP and Genetic Resources, Traditional Knowledge & Traditional Cultural Expressions
  • English

Insights

All related insights